News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Video
13 January 2026

Dealmakers: Silvia Gavornikova, OECD

TXF spoke with Silvia Gavornikova, head of export credit and competition at the OECD, to outline the slight uptick in overall support by ECAs under the Arrangement, as well as...

Interview
16 January 2026

Strategic insight: Turning up the dial on export finance...

Laura Galvin, JP Morgan’s new head of export and agency finance, talks to TXF about her priorities in a changing market, particularly amid the bank’s own $1.5 trillion...